[Cutaneopulmonary sarcoidosis during pegylated interferon plus ribavirin therapy].
Sánchez-Ruano
J J
JJ
Artaza-Varasa
T
T
Gómez-Rodríguez
R
R
González de Frutos
C
C
Repiso-Ortega
A
A
Alcántara-Torres
M
M
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D012507:Sarcoidosis / Q000139:chemically induced*; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced*; D012871:Skin Diseases / Q000139:chemically induced*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a